These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The effects of castration, testosterone and oestrogen on epithelial and stromal growth and morphology of the Dunning (R3327H) prostatic adenocarcinoma. Damber JE; Landström M; Bergh A; Tomic R Scand J Urol Nephrol Suppl; 1988; 110():145-8. PubMed ID: 3187402 [No Abstract] [Full Text] [Related]
23. [Principles for the conservative drug therapy treatment of prostate cancer]. Hofmann W Z Urol Nephrol; 1981 Sep; 74(9):697-704. PubMed ID: 7314992 [No Abstract] [Full Text] [Related]
24. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate]. Culine S Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025 [No Abstract] [Full Text] [Related]
25. Primary metastatic carcinoma of the prostate in younger men: a plea to think over usual therapeutic strategies. Maier U; Höbarth K; Simak R Eur Urol; 1996; 29(2):221-3. PubMed ID: 8647151 [TBL] [Abstract][Full Text] [Related]
26. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. Klotz L; Schellhammer P; Carroll K BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600 [No Abstract] [Full Text] [Related]
27. Simultaneous endocrine management and chemotherapy as initial treatment in M1 prostatic carcinoma. Richards B Prog Clin Biol Res; 1988; 269():177-86. PubMed ID: 2839846 [No Abstract] [Full Text] [Related]
28. [Treatment of prostatic cancer. The Finnish Academy and Duodecim]. Duodecim; 1993; 109(19):1695-704. PubMed ID: 7736990 [No Abstract] [Full Text] [Related]
29. [Evaluation of efficacy of cyproterone acetate monotherapy in prostatic cancer]. Gurina LI; Iudin SV; Rusakov IG; Bystrov AA Urologiia; 2003; (4):25-30. PubMed ID: 12942722 [TBL] [Abstract][Full Text] [Related]
30. Combined androgen blockade: the gold standard for metastatic prostate cancer. McLeod DG; Crawford ED; DeAntoni EP Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789 [TBL] [Abstract][Full Text] [Related]
31. Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer? Aragon-Ching JB Future Oncol; 2013 May; 9(5):619-22. PubMed ID: 23647288 [No Abstract] [Full Text] [Related]
33. The role of chemotherapy in the treatment of prostatic carcinoma. Tonato M; Bracarda S Rays; 1993; 18(1):87-93. PubMed ID: 8356244 [No Abstract] [Full Text] [Related]
34. [Combined hormone-chemotherapy for stage D2 prostatic cancer: starting time of chemotherapy in relation to hormone therapy]. Tsukamoto T; Fukui I; Kihara K; Goto S; Kitahara S; Kobayashi T; Kojima S; Oshima H Hinyokika Kiyo; 1996 May; 42(5):351-6. PubMed ID: 8752537 [TBL] [Abstract][Full Text] [Related]
36. [Metastatic cancer of the prostate: course, diagnosis and therapeutic management]. Wisard M; Gabellon S Rev Med Suisse Romande; 1995 Mar; 115(3):241-7. PubMed ID: 7777765 [No Abstract] [Full Text] [Related]
37. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program]. Mansueto G; Longo F Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169 [No Abstract] [Full Text] [Related]
38. [Incorrect about hormone treatment in prostatic cancer]. Fosså SD; Egey A; Haukaas SA; Angelsen A; Klepp O; Berge V; Axcrona K; Lilleby W Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429. PubMed ID: 19247406 [No Abstract] [Full Text] [Related]
39. Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer. Simmons MN; Klein EA Urology; 2009 Apr; 73(4):697-705. PubMed ID: 19185908 [No Abstract] [Full Text] [Related]
40. The benefits of early androgen blockade. Maroni PD; Crawford ED Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]